Disability News and Research

RSS

Infliximab biosimilar CT-P13 improves disease activity in patients with Ankylosing Spondylitis

New data presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) show that the newly-approved infliximab biosimilar CT-P13 achieves statistically similar improvements in disease activity, disability and mobility in patients with Ankylosing Spondylitis (AS) compared to its original reference product infliximab (INX).

13 Jun 2014

PD MED trial: Levodopa drug better for long-term treatment of newly diagnosed PD

For long-term treatment of newly diagnosed Parkinson’s disease (PD), the old drug levodopa provides better mobility and a higher quality of life than the two main alternatives, dopamine agonists (DA) and monoamine oxidase type B inhibitors (MAOBI), according to the largest-ever trial of PD treatment (PD MED), published in The Lancet.

13 Jun 2014

New advanced treatment can make huge difference for patients who suffer "brain attack"

When car crash victims suffer serious injuries, emergency crews often get them to trauma centers for the advanced care they need.

13 Jun 2014

Use of opioid linked to higher levels of dissatisfaction following spine surgery

A new study appearing in the Journal of Bone and Joint Surgery (JBJS) links the use of opioid pain relievers (prescription medications, such as Percocet) to less improvement and higher levels of dissatisfaction following spine surgery.

13 Jun 2014

U.S. cancer survivors face economic burdens due to growing medical costs, productivity losses

U.S. cancer survivors face significant economic burdens due to growing medical costs, missed work, and reduced productivity, according to a study by the Centers for Disease Control and Prevention in today's Morbidity and Mortality Weekly Report.

12 Jun 2014

Osteoarthritis patients treated with SoluMatrix meloxicam report greater pain relief

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today will present Phase 3 results that showed osteoarthritis (OA) patients treated with investigational SoluMatrix meloxicam 5 mg and 10 mg, a low dose nonsteroidal anti-inflammatory drug (NSAID), reported significantly greater pain relief compared with placebo.

12 Jun 2014

High-protein diets lower stroke risk

People with diets higher in protein, especially from fish, may be less likely to have a stroke than those with diets lower in protein, according to a meta-analysis published in the June 11, 2014, online issue of Neurology, the medical journal of the American Academy of Neurology.

12 Jun 2014

Targeted brain training can help improve cognitive performance in teens with traumatic brain injuries

Traumatic brain injuries from sports, recreational activities, falls or car accidents are the leading cause of death and disability in children and adolescents. While previously it was believed that the window for brain recovery was at most one year after injury, new research from the Center for BrainHealth at The University of Texas at Dallas published online today in the open-access journal Frontiers in Neurology shows cognitive performance can be improved to significant degrees months, and even years, after injury, given targeted brain training.

12 Jun 2014

Cancer drug offers protection against thrombosis

Case Western Reserve University researchers have discovered that an existing drug used to help cancer patients has the potential to protect thousands of others from the often-deadly impact of vascular clots.

12 Jun 2014

Exercise transiently suppresses inflammation in rheumatic disease

Research findings presented today at the European League Against Rheumatism Annual Congress suggest that exercise transiently suppresses local and systemic inflammation, reinforcing the beneficial effects of exercise and the need for this to be regular in order to achieve clinical efficacy in rheumatic disease.

12 Jun 2014

Findings provide new strategy for developing safe, effective vaccine against strep throat

An international team of scientists, led by researchers at the University of California, San Diego School of Medicine, have identified the genes encoding a molecule that famously defines Group A Streptococcus (strep), a pathogenic bacterial species responsible for more than 700 million infections worldwide each year.

12 Jun 2014

Study identifies correlation between miRNAs and osteoarthritis

The results of a study presented today at the European League Against Rheumatism Annual Congress identify a correlation between the presence of biomarkers in the blood, known as micro RNAs (miRNAs), and the development of severe osteoarthritis (OA) of the knee or hip joint. The findings suggest that miRNAs may be used as biomarkers to predict severe OA disease in individuals.

12 Jun 2014

Celgene: OTEZLA phase III study for psoriatic arthritis meets primary endpoint

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced results of additional analyses from the phase III clinical trials of OTEZLA, the Company's oral, selective inhibitor of phosphodiesterase 4 (PDE4).

11 Jun 2014

Study: Lifetime cost of supporting person with autism could be in millions

Researchers listed among the main factors contributing to this price tag were special education for children and residential care for adults as well as lost productivity for parents.

11 Jun 2014

First Edition: June 10, 2014

Today's headlines include details of an extensive, nationwide audit of the wait times for care at VA hospitals and clinics.

10 Jun 2014

Aetna partners with Fresenius Medical Care to improve lives of people with end stage renal disease

Fresenius Medical Care announced today a collaborative care model designed to improve the quality of care for Aetna's Medicare Advantage members who have end stage renal disease, while lowering health care costs.

10 Jun 2014

Study: Lifetime costs for individual with autism spectrum disorder may reach $2.4 million

Costs for a lifetime of support for each individual with autism spectrum disorder may reach $2.4 million, according to a new study from researchers from the Perelman School of Medicine at the University of Pennsylvania and the Children's Hospital of Philadelphia.

10 Jun 2014

Disability News and Research

Infliximab biosimilar CT-P13 improves disease activity in patients with Ankylosing Spondylitis

PD MED trial: Levodopa drug better for long-term treatment of newly diagnosed PD

New advanced treatment can make huge difference for patients who suffer "brain attack"

Use of opioid linked to higher levels of dissatisfaction following spine surgery

U.S. cancer survivors face economic burdens due to growing medical costs, productivity losses

Osteoarthritis patients treated with SoluMatrix meloxicam report greater pain relief

High-protein diets lower stroke risk

Targeted brain training can help improve cognitive performance in teens with traumatic brain injuries

Cancer drug offers protection against thrombosis

Exercise transiently suppresses inflammation in rheumatic disease

Findings provide new strategy for developing safe, effective vaccine against strep throat

Study identifies correlation between miRNAs and osteoarthritis

Celgene: OTEZLA phase III study for psoriatic arthritis meets primary endpoint

Study: Lifetime cost of supporting person with autism could be in millions

First Edition: June 10, 2014

Aetna partners with Fresenius Medical Care to improve lives of people with end stage renal disease

Study: Lifetime costs for individual with autism spectrum disorder may reach $2.4 million

Function restoration benefits for fibromyalgia in musculoskeletal disorders

Contacta to manufacture HLD large area hearing loop product platform in the USA

International leaders redefine phenotypes of multiple sclerosis

Lab Matters host Harriet Gould on building a more connected lab community

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

Latest News